BSE - Free Realtime Quote INR

Biocon Limited (BIOCON.BO)

288.45 -1.10 (-0.38%)
As of 2:41 PM GMT+5:30. Market Open.
Loading Chart for BIOCON.BO
DELL
  • Previous Close 289.55
  • Open 292.00
  • Bid 288.10 x --
  • Ask 288.40 x --
  • Day's Range 288.10 - 293.25
  • 52 Week Range 217.50 - 307.00
  • Volume 191,896
  • Avg. Volume 476,677
  • Market Cap (intraday) 345.217B
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) 28.79
  • EPS (TTM) 10.02
  • Earnings Date May 16, 2024
  • Forward Dividend & Yield 1.50 (0.52%)
  • Ex-Dividend Date Jul 7, 2023
  • 1y Target Est 592.06

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, the company is involved in the integrated discovery, development, and manufacturing services for small and large molecules. It serves customers in approximately 120 countries. The company was incorporated in 1978 and is headquartered in Bengaluru, India.

www.biocon.com

16,545

Full Time Employees

March 31

Fiscal Year Ends

Recent News: BIOCON.BO

Performance Overview: BIOCON.BO

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BIOCON.BO
15.50%
S&P BSE SENSEX
3.10%

1-Year Return

BIOCON.BO
27.89%
S&P BSE SENSEX
24.01%

3-Year Return

BIOCON.BO
27.30%
S&P BSE SENSEX
55.55%

5-Year Return

BIOCON.BO
5.83%
S&P BSE SENSEX
90.70%

Compare To: BIOCON.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIOCON.BO

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    346.53B

  • Enterprise Value

    489.75B

  • Trailing P/E

    28.87

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.47

  • Price/Book (mrq)

    1.83

  • Enterprise Value/Revenue

    3.49

  • Enterprise Value/EBITDA

    11.59

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.21%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    146.12B

  • Net Income Avi to Common (ttm)

    12B

  • Diluted EPS (ttm)

    10.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    37.86B

  • Total Debt/Equity (mrq)

    75.18%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: BIOCON.BO

Analyst Price Targets

300.00
592.06 Average
288.45 Current
850.00 High
 

Earnings

Consensus EPS
 

Company Insights: BIOCON.BO

People Also Watch